Lopedote Paolo, Nawaiseh Ahmad Al, Malek Anita, Faller Garrey, Hattar Mariana, Dow Edward, Kozyreva Olga
Department of Medicine, St Elizabeth's Medical Center, Boston University, Boston, MA, United States.
Department of Pathology, St Elizabeth's Medical Center, Boston, MA, United States.
Leuk Res Rep. 2023 Aug 22;20:100384. doi: 10.1016/j.lrr.2023.100384. eCollection 2023.
Splenic diffuse red pulp small B-cell lymphoma (SDRPL) is a rare entity. Diagnosis is typically achieved with splenectomy and most patients remain in remission after this intervention. Hemoglobin value less than 10 g/dL and NOTCH1, TP53, and MAP2K1 gene mutations at diagnosis have been associated with worse outcome. Progression after splenectomy of SDRPL is possible, although transformation to aggressive lymphoma has rarely been reported. We herein report the case of a patient formerly diagnosed with SDRPL with gene mutations involving CREBBP, NOTCH1, ARID2, and TNFRSF14 who transformed to diffuse large B-cell lymphoma six months after splenectomy.
脾弥漫性红髓小B细胞淋巴瘤(SDRPL)是一种罕见的疾病。诊断通常通过脾切除术来实现,大多数患者在这种干预后仍处于缓解状态。诊断时血红蛋白值低于10 g/dL以及NOTCH1、TP53和MAP2K1基因突变与较差的预后相关。SDRPL脾切除术后有可能进展,尽管转化为侵袭性淋巴瘤的情况很少见。我们在此报告一例先前诊断为SDRPL的患者,其基因突变涉及CREBBP、NOTCH1、ARID2和TNFRSF14,在脾切除术后六个月转化为弥漫性大B细胞淋巴瘤。